PharmaMar and Eczacıbaşı sign a licensing agreement for Aplidin in Turkey
Aplidin is PharmaMar's second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.
PharmaMar has announced a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey. Under the terms of the agreement, PharmaMar will receive an upfront payment as well as development milestones related to the health approval procedure of Aplidin in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacıbaşı for commercial use.
Aplidin is PharmaMar's second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma and in September 2016, PharmaMar presented to the EMA the submission of the Marketing Authorization Application for this drug in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma.
"The partnership with Eczacıbaşı will help in the commercialization in Turkey of plitidepsin, developed to tackle hematologic cancer. We are looking forward to working with one of the leading Health Care companies in this country," said Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit. "We are firmly committed to advancing in the development of innovative oncology therapies", he added.
Atalay Gümrah, CEO and President of the Eczacıbaşı Group, stated: "The agreement between PharmaMar and Eczacıbaşı Pharmaceuticals Marketing (EIP) offered a major advance for healthcare in Turkey, as Aplidin represented the latest innovation in cancer treatment." Elif Çelik, Executive Vice President of the Eczacıbaşı Healthcare Division, noted that "the agreement ensured that multiple myeloma patients in Turkey would have access to the most innovative treatment at the same time as patients in other EU countries". She added that "the two parties hoped to extend the partnership to innovative products in other treatment areas as well".
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.